Harbour Investments’s Clearside Biomedical CLSD Stock Holding History

Harbour Investments’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27	Closed	-$2K	–	2804
2021 Q3	$2K	Hold	27	–	–	﹤0.01%	3278
2021 Q2	$2K	Buy	+27	New	+$1.25K	﹤0.01%	3351

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbour Investments's CLSD Position: Q4 2021 in Review

Harbour Investments sold out of Clearside Biomedical (CLSD) in Q4 2021, closing a stake of 27 shares — an estimated $2K sold.

Harbour Investments first reported a position in CLSD in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 67 funds tracked by Wall St. Rank hold CLSD as of Q4 2021.

Harbour Investments reported no remaining Clearside Biomedical position as of Q4 2021 after selling out during the quarter.
Harbour Investments sold 27 Clearside Biomedical shares in Q4 2021, an estimated $2K.
Harbour Investments first reported a position in Clearside Biomedical in Q2 2021 and held it in 2 quarters.
Harbour Investments's Clearside Biomedical position peaked at $2K in Q3 2021.
67 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.